This study is investigating the neurodevelopmental effects of prenatal exposure to lamotrigine (LTG), sodium valproate (VPA), or carbamazepine (CBZ) monotherapies. The hypotheses to be tested include: 1. Exposure during pregnancy to CBZ, LTG, and VPA, each as monotherapy, is associated with developmental delay with or without signs of autism. 2. Exposure to each drug (CBZ, LTG, and VPA) as monotherapy is associated with an increased rate of occurrence of major malformations. 3. The child with major malformations is more likely to have developmental delay with or without signs of autism than the child who does not have major malformations. 4. The occurrence of adaptive behavior outcomes will show a dose-response relationship with the dose of medication taken by the mother in the first trimester. The study population includes children 36-83 months of age who were exposed throughout gestation to one of the three drugs of interest, as treatment for maternal seizure disorder.
Study Type
OBSERVATIONAL
Enrollment
298
Massachusetts General Hospital
Boston, Massachusetts, United States
Adaptive Behavior Scores
Measures of each child's Adaptive Behavior scores as assessed by the Vineland-II Adaptive Behavior Scales, collected when the child was between 36 and 83 months of age.
Time frame: 36-83 months of age
Presence/Absence of Major Malformations
Based on interview with mother and review of medical records, determination is made as to whether or not the child had any major malformations at birth.
Time frame: 36-83 months of age
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.